The stock of Fulcrum Therapeutics Inc (NASDAQ:FULC) last traded at $3.18, down -7.56% from the previous session.
FULC stock price is now -62.24% away from the 50-day moving average and -59.85% away from the 200-day moving average. The market capitalization of the company currently stands at $198.43M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target reduced from $17 to $4, H.C. Wainwright Downgraded its rating from Buy to Neutral for Fulcrum Therapeutics Inc (NASDAQ: FULC). , while ‘RBC Capital Mkts’ rates the stock as ‘Sector Perform’
In other news, Tourangeau Greg, Principal Accounting Officer sold 236 shares of the company’s stock on May 07 ’24. The stock was sold for $1,831 at an average price of $7.76. Upon completion of the transaction, the Principal Accounting Officer now directly owns 11,571 shares in the company, valued at $36795.78. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 08 ’24, Vice President, Finance Tourangeau Greg sold 4,884 shares of the business’s stock. A total of $57,219 was realized by selling the stock at an average price of $11.72. This leaves the insider owning 11,807 shares of the company worth $37546.26. A total of 7.48% of the company’s stock is owned by insiders.
During the past 12 months, Fulcrum Therapeutics Inc has had a low of $2.87 and a high of $13.70. As of last week, the company has a debt-to-equity ratio of 0.04, a current ratio of 22.07, and a quick ratio of 22.07. The fifty day moving average price for FULC is $8.3617 and a two-hundred day moving average price translates $7.911975 for the stock.
The latest earnings results from Fulcrum Therapeutics Inc (NASDAQ: FULC) was released for 2024-06-30. The net profit margin was -24.79% and return on equity was -7.37% for FULC. The company reported revenue of $80.0 million for the quarter, compared to $0.88 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 8990.91 percent.
